Ian Elliott Krop, MD, Ph.D., is the Chief of Breast Medical Oncology and the Director of Clinical Research for the Breast Oncology Program at Dana-Farber Cancer Institute. He is also an Associate Professor of Medicine at Harvard Medical School.
Dr. Krop is a translational investigator focused on the development of novel molecularly targeted therapies and immunotherapies for breast cancer, and elucidating the mechanisms of resistance to these treatments. The majority of his effort is concentrated in the area of HER2+ breast cancer. He was a leader in the development of the antibody-drug conjugate trastuzumab emtansine (T-DM1).
Dr. Krop is a member of the National Cancer Institute’s Breast Cancer Steering Committee and co-chairs its Immuno-Oncology Working Group. He is also the co-vice chair for correlative science for the Alliance for Clinical Trials in Oncology. He is a member of the Eastern Cooperative Oncology Group Data Monitoring Committee and is co-chair of the HER2-working group of the Translational Breast Cancer Research Consortium.
Dr. Krop is a graduate of Johns Hopkins University and Johns Hopkins University School of Medicine. He trained at Johns Hopkins Hospital, Dana-Farber Cancer Institute, Harvard Medical School, and Brigham and Women’s Hospital. He completed a medical oncology fellowship at Dana-Farber.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)